HC Wainwright & Co. Maintains Buy on Tango Therapeutics, Raises Price Target to $66

Benzinga Newsdesk www.benzinga.com Positive 75.6%

Neg 0% Neu 0% Pos 75.6%

HC Wainwright & Co. analyst Robert Burns maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and raises the price target from $27 to $66.